ID: ALA5198434

Max Phase: Preclinical

Molecular Formula: C37H49N11O2

Molecular Weight: 679.87

Associated Items:

Representations

Canonical SMILES:  C[C@H]1CCCCN1c1nnc2ccc(O[C@@H]3CC[C@H](NC(=O)Nc4cc(C(C)(C)C)nn4-c4ccn(CCN(C)C)n4)c4ccccc43)cn12

Standard InChI:  InChI=1S/C37H49N11O2/c1-25-11-9-10-19-46(25)36-41-40-32-17-14-26(24-47(32)36)50-30-16-15-29(27-12-7-8-13-28(27)30)38-35(49)39-34-23-31(37(2,3)4)42-48(34)33-18-20-45(43-33)22-21-44(5)6/h7-8,12-14,17-18,20,23-25,29-30H,9-11,15-16,19,21-22H2,1-6H3,(H2,38,39,49)/t25-,29-,30+/m0/s1

Standard InChI Key:  PTMREIGUVZHIEP-JPHFWNGBSA-N

Associated Targets(Human)

MAP kinase p38 alpha 12866 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 679.87Molecular Weight (Monoisotopic): 679.4071AlogP: 6.13#Rotatable Bonds: 9
Polar Surface Area: 122.67Molecular Species: BASEHBA: 11HBD: 2
#RO5 Violations: 3HBA (Lipinski): 13HBD (Lipinski): 2#RO5 Violations (Lipinski): 3
CX Acidic pKa: 12.41CX Basic pKa: 8.66CX LogP: 5.95CX LogD: 4.67
Aromatic Rings: 5Heavy Atoms: 50QED Weighted: 0.19Np Likeness Score: -1.46

References

1. Armani E, Capaldi C, Bagnacani V, Saccani F, Aquino G, Puccini P, Facchinetti F, Martucci C, Moretto N, Villetti G, Patacchini R, Civelli M, Hurley C, Jennings A, Alcaraz L, Bloomfield D, Briggs M, Daly S, Panchal T, Russell V, Wicks S, Finch H, Fitzgerald M, Fox C, Delcanale M..  (2022)  Design, Synthesis, and Biological Characterization of Inhaled p38α/β MAPK Inhibitors for the Treatment of Lung Inflammatory Diseases.,  65  (10.0): [PMID:35546685] [10.1021/acs.jmedchem.2c00115]

Source